Head and neck cancer is the sixth most common cancer across the globe. This is generally
associated with tobacco and alcohol consumption. Cancer in the pharynx majorly arises …

c-MET is a receptor tyrosine kinase that, after binding with its ligand, hepatocyte growth
factor, activates a wide range of different cellular signaling pathways, including those …

Because of the critical roles of aberrant signaling in cancer, both c-MET and ALK receptor
tyrosine kinases are attractive oncology targets for therapeutic intervention. The cocrystal …

Despite continuous improvements in research and new cancer therapeutics, the goal of
eradicating cancer remains elusive because of drug resistance. For a long time, drug …

The Src family of non-receptor protein tyrosine kinases plays critical roles in a variety of
cellular signal transduction pathways, regulating such diverse processes as cell division …

Cancer is a condition that has plagued humanity for thousands of years, with the first
depictions dating back to ancient Egyptian times. However, not until recent decades have …

Non–small cell lung cancer (NSCLC) is a difficult disease to treat. The c-Met receptor is an
attractive potential target for novel therapeutic inhibition in human cancers. We provide …

Studies on signal transduction pathways have generated various promising molecular
targets for therapeutic inhibition in cancer therapy. Receptor tyrosine kinases represent an …

Receptor tyrosine kinase (RTK) targeted agents such as trastuzumab, imatinib,
bevacizumab, and gefitinib inhibitors have illustrated the utility of targeting this protein class …

Small cell lung cancer (SCLC) is an aggressive cancer, and most patients present with
cancer already spread beyond the lung. The receptor tyrosine kinase (RTK) c-MET has been …